Table 1.
Baseline characteristics of 27 patients with relapsed or refractory multiple myeloma (RRMM)
| Characteristic | No. of patients (%) |
|---|---|
| Agea (years) | 56 (36–77) |
| Sex | |
| Men | 18 (66.7) |
| Women | 9 (33.3) |
| ISS stageb | |
| I | 6 (23.1) |
| II | 14 (53.8) |
| III | 6 (23.1) |
| Time since diagnosisa (months) | 21 (4–60) |
| Subtype of disease | |
| IgG | 11 (40.7) |
| IgA | 6 (22.2) |
| IgD | 5 (18.5) |
| Light chain | 5 (18.5) |
| β2-microglobulinb | |
| Levela (mg/L) | 3.4 (1.1–16.7) |
| <3.5 mg/L | 14 (53.8) |
| ≥3.5 mg/L | 12 (46.2) |
| Prior therapy | |
| Numbera (cycles) | 3 (1–8) |
| 0–3 cycles | 14 (51.9) |
| >3 cycles | 13 (48.1) |
| Prior regimen | |
| Glucocorticoids | 25 (92.6) |
| Alkylating agents | 23 (85.2) |
| IMiDs (thalidomide or lenalidomide) | 21 (77.8) |
| Vincristine | 19 (70.3) |
| Bortezomib | 14 (51.9) |
| Both bortezomib and IMiDs | 9 (33.3) |
| Autologous stem cell transplantation | 5 (18.5) |
ISS international staging system, IMiDs immunomodulatory drugs
aThese values are presented as median followed by ranges in the parentheses; other values are presented as number of patients followed by percentages in the parentheses
bBaseline β2-microglobulin was not determined in one patient; who could not be grouped into any ISS stage